Blue Matter Blog

What challenges could Biogen’s Aduhelm (aducanumab) face as it goes to market?
June 28, 2021

Biogen’s Aduhelm® (aducanumab) is the fist potentially disease-modifying therapy approved for Alzheimer’s disease.  However, it could face some significant challenges as it goes to market. Varun Renjen, M.D., describes the three main ones in this short video. Link here.

What impact is Biogen’s Aduhelm (aducanumab) likely to have on the Alzheimer’s Market?
June 24, 2021

On June 7, 2021, the FDA approved Biogen’s Aduhelm® (aducanumab) for Alzheimer’s disease.  As the first potentially disease-modifying therapy for Alzheimer’s, it could have some significant impacts on the market for Alzheimer’s therapies. Varun Renjen, M.D., outlines those potential impacts in this short video. Link here

Upcoming Webinar: Psychedelics in CNS Therapeutics
June 21, 2021

Don’t miss this informative webinar on Tuesday, July 20 at 11:00 am EDT. Register here. Psychedelics and other traditionally taboo substances are undergoing a bit of a “renaissance” in central nervous system (CNS) therapeutics. These types of substances have a long and storied history around the world. Now, research into their potential therapeutic benefits is …

Alzheimer’s Disease: An In-Depth Look at a Formidable Foe
June 8, 2021

There is no shortage of disabling and deadly diseases in the world.  However, few match Alzheimer’s disease (AD) when it comes to sheer ability to cause fear and dread.  It’s not a rare disease.  In fact, it’s on the rise.  There is no cure (nor effective treatment yet) and it’s ultimately fatal.  And, most frightening, …

Beyond Linear Drug Development: Leveraging the Constellation Approach in Rare Diseases
June 7, 2021

We gratefully acknowledge the contributions of Alyssa Manz, Ph.D. and Quinn Civik for their work on the data analysis which supports this publication. Each rare disease (RD) only impacts a relatively small population, and given the clinical breadth of these conditions, new RD product development may feel like forging a completely new path towards a …

An Overview of Cross-Border Collaborations on Healthcare Technology Assessment, Pricing Negotiation, and Procurement
June 3, 2021

In our previous paper, we discussed several trends shaping the European market access landscape. Here, we explore recent cross border collaborations in more detail. While the recent COVID response highlighted many challenges, payers are making (slow) progress on a range of ongoing or planned initiatives: Small groups of countries conducting joint healthcare technology assessment (HTA) …